AlphaCognition, Inc., a biopharmaceutical company, discovers and develops bioactive compounds for treatments of Alzheimer's and Lou Gehrig's disease. It develops Alpha-1062, for the treatment of mild to moderate Alzheimer's disease, and Alpha-602, for the treatment of amyotrophic lateral sclerosis (ALS). The company was formerly known as Neurodyn Cognition Inc. and changed its name to AlphaCognition, Inc. in March 2020. The company was incorporated in 2014 and is based in Vancouver, Canada with additional offices in Charlottetown, Canada; and West Palm Beach, Florida.